1-7 of 7
Wolfgang Eiermann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martín, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1854–1862.
https://doi.org/10.1158/1078-0432.CCR-21-1762
Published: 02 May 2022
View article titled, Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Open the PDF for Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O'Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, Wolfgang Eiermann, Tadeusz Pienkowski, Miguel Martin, Nicholas Robert, John Crown, Paolo Nuciforo, Valerie Bee, John Mackey, Dennis J. Slamon, Michael F. Press
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (9): 2065–2074.
https://doi.org/10.1158/1078-0432.CCR-14-2993
Published: 30 April 2015
View article titled, PTEN Loss Is Associated with Worse Outcome in <em>HER2</em>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Open the PDF for PTEN Loss Is Associated with Worse Outcome in <em>HER2</em>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Aleix Prat, Giampaolo Bianchini, Marlene Thomas, Anton Belousov, Maggie C.U. Cheang, Astrid Koehler, Patricia Gómez, Vladimir Semiglazov, Wolfgang Eiermann, Sergei Tjulandin, Mikhail Byakhow, Begoña Bermejo, Milvia Zambetti, Federico Vazquez, Luca Gianni, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 511–521.
https://doi.org/10.1158/1078-0432.CCR-13-0239
Published: 16 January 2014
View article titled, Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Open the PDF for Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study in another window
Includes: Supplementary data
Journal Articles

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

Gunter von Minckwitz, Wolfgang D. Schmitt, Sibylle Loibl, Berit M. Müller, Jens U. Blohmer, Bruno V. Sinn, Holger Eidtmann, Wolfgang Eiermann, Bernd Gerber, Hans Tesch, Jörn Hilfrich, Jens Huober, Tanja Fehm, Jana Barinoff, Thomas Rüdiger, Erhard Erbstoesser, Peter A. Fasching, Thomas Karn, Volkmar Müller, Christian Jackisch, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4521–4531.
https://doi.org/10.1158/1078-0432.CCR-12-3628
Published: 13 August 2013
View article titled, Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Open the PDF for Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

Sara A. Hurvitz, David J. Betting, Howard M. Stern, Emmanuel Quinaux, Jeremy Stinson, Somasekar Seshagiri, Ying Zhao, Marc Buyse, John Mackey, Adrian Driga, Sambasivarao Damaraju, Mark X. Sliwkowski, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martin, Valerie Bee, Omkar Marathe, Dennis J. Slamon, John M. Timmerman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3478–3486.
https://doi.org/10.1158/1078-0432.CCR-11-2294
Published: 14 June 2012
View article titled, Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Open the PDF for Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

Luca Gianni, José Baselga, Wolfgang Eiermann, Vicente Guillem Porta, Vladimir Semiglazov, Aña Lluch, Milvia Zambetti, Dolores Sabadell, Günther Raab, Antonio Llombart Cussac, Alla Bozhok, Angel Martinez-Agulló, Marco Greco, Mikhail Byakhov, Juan Josè Lopez Lopez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna, European Cooperative Trial in Operable Breast Cancer Study Group
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8715–8721.
https://doi.org/10.1158/1078-0432.CCR-05-0539
Published: 16 December 2005
View article titled, Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Open the PDF for Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy in another window
Journal Articles

Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer

Giulia Bianchi, John Albanell, Wolfgang Eiermann, Giordano Vitali, David Borquez, Lucia Viganò, Rafael Molina, Günter Raab, Alberta Locatelli, Bart Vanhauwere, Luca Gianni, Jose Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5944–5951.
Published: 15 December 2003
View article titled, Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer
Open the PDF for Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer in another window